A study in syngeneic MM model indicated that ARG1 might play a role in suppressing antitumor immune response—intraperitoneal (i.p.)administration of recombinant ARG1 into mice with NS-1 MM significantly shortened the survival of tumor-bearing animals and impaired NK cells activity17. This evidence concerns the gene ARG1 and Miyoshi myopathy.